

## 20<mark>20</mark> Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteriaceae Multi-site Gram-Negative Surveillance Initiative (MuGSI)

## Healthcare-Associated Infections Community Interface (HAIC) Case Report

Form Approved OMB No. 0920-0978 Exp. Date: XX-XX-XXXX

						•	, ·				
Patient's Name	:				P	Phone no. (	)				
Address:							MRN:				
City: State					ZIP: Hospital:						
Patient Identifier information is not transmitted to CDC											
DEMOGRAPHICS											
1. STATE:	2. COUNTY:	3. STATE ID:			4a. LABORATORY ID W INCIDENT SPECIMEN ID		4b. FACILITY ID WHERE PATIENT TREATED:				
5. DATE OF BIR	TH:	7. SEX AT BIR	TH:	8а. Ет	HNIC ORIGIN: 8b. RACE: (Check all that Apply)						
			FEMALE	1_	lispanic or Latino lot Hispanic or Latino	☐ Ame Nati	erican Indian or Alaska				
6. AGE: Unknown		'n	1_	·	☐ Asia	ın	☐ White				
☐ Days	☐ Mos. ☐ Yrs.		transgender		Inknown	☐ Blac	ck or African American 🔲 Unknown				
	IDENT SPECIMEN COLL	` ,		Escheric	ed-Spectrum Cephalosporin-resistant: ichia coli Ila pneumoniae						
11. INCIDENT SP	ECIMEN COLLECTION S	SITE:									
☐ Blood ☐	Bone CSF	☐ Internal bo	ody site (speci	fy):	Doint/synd	ovial fluid	☐ Muscle				
☐ Peritoneal f	luid 🗌 Pericardi	al fluid	eural fluid [	☐ Urine	☐ Other normally st	terile site (sp	ecify):	_			
12. LOCATION O	ION:		13. WHERE WAS THE F	PATIENT LOCA	TED ON THE 3RD CALENDA	AR DAY BEFORE THE					
□ OUTPATIENT: □ INPATIENT: □ LTCF											
Facility	Facility		Facility ID:		☐ Private residence ☐ LTACH ☐ LTCF Facility ID:						
ID: ☐ Emergenc	—— ID: <sup>y room</sup> □ ICU		LTACH		LTCF						
☐ Clinic/Doct	or's office	Facility		Facility ID:							
☐ Dialysis ce	OR	ID:		☐ Hospital inpatient Facility ID:		☐ Incarcerated					
☐ Surgery	☐ Rad	ology					Other (specify):				
☐ Observation	nal/	er inpatient			Was the patient tran this hospital?	isterred from	om □ Unknown				
Clinical decision unit  ☐ Unknown ☐ Unknown				n	□ Yes □ No □ Unknown						
	ATIENT HOSPITALIZED		IN THE		15a. WAS THE PATIENT IN AN ICU IN THE 7 DAYS BEFORE THE DISC?  ☐ Yes ☐ No ☐ Unknown						
					IF YES, DATE OF ICU ADMISSION: OR Date unknown						
	Io Unknown  ADMISSION:				15b. WAS THE PATIENT IN AN ICU ON THE DAY OF INCIDENT SPECIMEN COLLECTION OR IN THE 6 DAYS AFTER THE DISC?  Yes No Unknown						
							<u>.</u>	OR			
16. PATIENT OF	JTCOME: Surv	ived			Died			Unknown			
DATE OF DISCHARGE.											
DATE OF DISCHARGE OR Date unknown  Date unknown Left against medical advice (AMA)											
IF SURVIVED, DI		-	`					EATH, WAS THE PATHOGEN			
☐ Private resid	lence 🗌 LTCF Fac	ility ID:	LTACH Fac	ility ID:	OF INTEREST ISO	LATED FROM	A SITE THAT MEETS THE C	ASE DEFINITION?			
	ify):										
Public reporting burde	en of this collection of informa	ation is estimated to aver	rage 25 minutes per	response, in	cluding the time for reviewing ins	tructions, searchir	ng existing data sources, gathering	g and maintaining the data needed,			

Public reporting burden of this collection of information is estimated to average 25 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978).





17a. Types of infection ass	SOCIATED	WITH CULTURE(S): (	Check all	that apply)	☐ None	☐ Unknown ☐ Color	uized	17V. F971 FF9BH1 H=	
—	□ Cellulitis	ulcer/wound (not decu		Epidural Abs Meningitis			al incision infection al site infection (internal)	☐ Yes	
		us/pressure ulcer	, c	Osteomyelitis		Septic emboli   Traum	atic wound `	□ No	
	<ul><li>□ Empyen</li><li>□ Endocar</li></ul>			Peritonitis Pneumonia		Septic shock	y tract infection (specify):	☐ Unknown	
18. UNDERLYING CONDITIONS	S: (Check a	II that apply)	None	Unknow			(		
CHRONIC LUNG DISEASE	(	IMMUNOCOMPROMIS		DITION	NEURO	LOGIC CONDITION	SKIN CONE	DITION	
□ Cystic fibrosis		□ HIV infection	+ + 000			ebral palsy	□ Burn		
☐ Chronic pulmonary disease		☐ AIDS/CD4 coun ☐ Primary immunod	eficiency			onic cognitive deficit nentia	<ul><li>□ Decubitu</li><li>□ Surgical</li></ul>	us/pressure ulcer	
CHRONIC METABOLIC DISEASE	E	☐ Transplant, hemat☐ Transplant, solid o		tem cell		epsy/seizure/seizure disorde iple sclerosis	r □ Other ch	ronic ulcer or chronic	
<ul> <li>□ Diabetes mellitus</li> <li>□ With chronic complications</li> </ul>		LIVER DISEASE	ngun		□ Neu	ropathy	wound □ Other (s	pecify):	
•	•	☐ Chronic liver disea	ise			xinson's disease er (specify):		· · · · · · · · · · · · · · · · · · ·	
CARDIOVASCULAR DISEASE  □ CVA/Stroke/TIA		<ul><li>☐ Ascites</li><li>☐ Cirrhosis</li></ul>					OTHER		
<ul><li>☐ Congenital heart disease</li><li>☐ Congestive heart failure</li></ul>		☐ Hepatic enceph				AS/PARALYSIS		ive tissue disease or morbid obesity	
☐ Myocardial infarction		<ul><li>□ Variceal bleedir</li><li>□ Hepatitis C</li></ul>	ıg			niplegia aplegia	□ Pregnan		
☐ Peripheral vascular disease (	(PVD)	<ul> <li>□ Treated, in SVR</li> <li>□ Current, chronic</li> </ul>			□ Qua	adriplegia	Mugsi Con	IDITIONS	
GASTROINTESTINAL DISEASE		MALIGNANCY	,		DEMA	Diograph		tract problems/	
<ul><li>□ Diverticular disease</li><li>□ Inflammatory bowel disease</li></ul>		☐ Malignancy, hema	atologic			DISEASE onic kidney disease	abnorm □ Premat		
□ Peptic ulcer disease		☐ Malignancy, solid	organ (no			rest serum creatinine:	mg/DL ☐ Spina b		
☐ Short gut syndrome		□ Malignancy, solid	organ (m	etastatic)		Unknown or not done			
19. SUBSTANCE USE		OTHER SUBS	TANCES	•		y) □ None □ Unknown E DISORDER (DUD)/ABUSE:	MODE OF DELIVERY: (	Chack all that apply	
SMOKING:		□ Marijuana	cannahing	oid (other than sr		□ DUD or abuse		□ Non-IDU □ Unknown	
	LCOHOL			e I (e.g., heroin)	nomig)	□ DUD or abuse		□ Non-IDU □ Unknown	
apply) □ None □ Unknown Al	BUSE:	Opioid, DE		e II-IV (e.g., met	hadone, oxy	codone)   DUD or abuse  DUD or abuse		□ Non-IDU □ Unknown □ Non-IDU □ Unknown	
	Yes	Cocaine	·S)			□ DUD or abuse		□ Non-IDU □ Unknown	
* *	No Unknown	☐ Methamph				<ul><li>□ DUD or abuse</li><li>□ DUD or abuse</li></ul>		□ Non-IDU □ Unknown □ Non-IDU □ Unknown	
<b>,</b>	Children	<ul><li>□ Other (spe</li><li>□ Unknown s</li></ul>				□ DUD or abuse		□ Non-IDU □ Unknown	
		DURING THE CURRE	NT HOSDI	TALIZATIONI DIE	THE DATIE	NT DECEIVE			
		MEDICATION ASSIST					No ☐ N/A (patient not hospi	talized or did not have DUD)	
20. RISK FACTORS: (Check al	II that apply	y) 🗆 None 🗆	Unkno	own		CENTRAL LINE IN PLACE COLLECTION), OR AT AN			
WAS INCIDENT SPECIMEN COLL DAYS AFTER HOSPITAL ADMISS		R MORE CALENDAR	□ Yes	□ No		DAYS BEFORE DISC:	□ Yes □ No □ Unk	nown	
						Check he	re if central line in place for	> 2 calendar days: □	
PREVIOUS HOSPITALIZATION IN	THE YEAR	BEFORE DISC:	□ Yes	□ No □ Un	known	URINARY CATHETER IN			
IF YES, DATE OF DISCHARGE	CLOSEST	то DISC :				THE TIME OF COLLECTION CALENDAR DAYS BEFORE	"	□ No □ Unknown	
OR, DATE UNKNOWN $\square$						IF YES, CHECK ALL			
Facility ID:						□ Indwelling Urethr	al Catheter □ Suprap	oubic Catheter	
OVERNIGHT STAY IN LTCF IN T	HE YEAR B	EFORE DISC:	⊓ Yes	□ No □ Ur	known	□ Condom Cathete	r 🗆 Other (	specify):	
Facility ID:						ANY OTHER INDWELLING	G DEVICE IN PLACE ON T	HE DISC (UP	
OVERNIGHT STAY IN LTACH IN	THE YEAR	BEFORE DISC:	⊓ Ves	□ No □ Ur	known	TO THE TIME OF COLLEC	CTION), OR AT ANY TIME	IN THE 2	
Facility ID:			□ 103		IKHOWH	CALENDAR DAYS BEFOR	REDISC: U Yes U	NO 🗆 Unknown	
						IF YES, CHECK ALL TH	IAT APPLY:		
SURGERY IN THE YEAR BEFORE	: DISC:		□ Yes	□ No □ Un	iknown	□ ET/NT Tube □ G	Gastrostomy Tube	□ NG Tube	
CURRENT CHRONIC DIALYSIS:			□ Yes	□ No □ Ur	nknown	□ Tracheostomy □ N	,	☐ Other (specify):	
IF YES, TYPE: ☐ Hemodialy	⁄sis □ Pe	eritoneal 🗆 Unkno	wn			-	-		
IF HEMODIALYSIS, TYPE OF	F VASCULA	AR ACCESS:				Damento de como de como			
□ AV fistula/graft □ Hem	nodialysis	central line □ Unk	nown			PATIENT TRAVELED INT IN THE YEAR BEFORE D	□ V <sub>Φ</sub>	s □ No □ Unknown	
21a. WEIGHT:	<b>21</b> b	. HEIGHT:		<mark>21</mark> с. вм	l:	COLINTRY			
lbsoz. Of		ft i			_	_	MILLI E MOLTINO		
kg 🗌 Unknown	_	_cm 🛮 Unknown		☐ Unkn	iown	PATIENT HOSPITALIZED COUNTRY(IES) ABOVE:	VVIILE VISITING ☐ Ye	s □ No □ Unknown	

Version Date: 01/2019 PAGE 2 OF 4





URINE CULTURES ONLY: 22, RECORD THE COLONY COUNT:	URINE CULTURES ONLY:  23, SIGNS AND SYMPTOMS A  Please indicate if any of the follow 2 calendar days before through the	wing symptom	s were rep	ported duri	ing the 5 d	-		_	
	□ None		□ Unkno	own			otoms for patients ear of age only:	<b>i</b>	
	☐ Costovertebral angle pain or te	enderness	□ Freque			□ Ap			
	□ Dysuria			pubic tend	lerness		radycardia		
	☐ Fever [temperature ≥ 100.4 °F	(38 °C)1	□ Urgen	-			ethargy		
	[	(/1	- 3	,			omiting		
24a. WAS THE INCIDENT SPECIMEN POLYMICROBIAL?	24b. WHAT SCREENING/ CONF METHOD WAS USED FOR ESBLIDENTIFICATION? (Check all that apply): \(\sumsymbol{\substack}\) None		M R				NFIRMATORY HAT WAS THE		
□Vos	☐ Broth Microdilution (ATI det	ection)							
□ Yes □ No	□ ESBL well			Positive	□ Negati	ive	□ Indeterminate	□ Unknown	
□ Unknown	□ Expert rule (ATI flag)			Positive	□ Negati		□ Indeterminate	□ Unknown	
- OTKHOWII	□ Unknown			Positive	□ Negati		□ Indeterminate	□ Unknown	
	☐ Broth Microdilution (Manual	)		Positive	□ Negati		□ Indeterminate	□ Unknown	
	□ Disk Diffusion			Positive	□ Negati		□ Indeterminate	□ Unknown	
	□ E-test			Positive	□ Negati		□ Indeterminate	□ Unknown	
	<ul><li>☐ Molecular test (specify):</li><li>☐ Other non-molecular test (s</li></ul>	:£.\.		☐ Positive☐ Positive☐	□ Negati □ Negati		<ul><li>□ Indeterminate</li><li>□ Indeterminate</li></ul>	□ Unknown □ Unknown	
	- Other Hori-Holesdadi test (s	pcony)							
□ Amoxicillin         □           □ Amoxicillin/clavulanic acid         □           □ Ampicillin         □           □ Ampicillin/sulbactam         □           □ Azithromycin         □           □ Aztreonam         □           □ Cefazolin         □           □ Cefotinir         □           □ Cefixime         □           □ Cefotaxime         □           □ Cefoxitin         □	Ceftazidime Ceftazidime Ceftazidime/avibactam Ceftizoxime Ceftizoxome Ceftrizone Ceftrizone Ceftrizone Cefuroxime Cefuroxime Cephalexin Ciprofloxacin Clarithromycin Clindamycin Dalbavancin Daptomycin Delafloxacin	Ertapenem   Fidaxomicin   Fosfomycin   Gentamicin   Imipenem/ci   Levofloxacir   Linezolid   Meropenem   Metronidazc   Moxifloxacir   Nitrofuranto	Check all			Unkno	Polymyxin B Polymyxin E (coli Rifaximin Tedizolid Telavancin Tigecycline Tobramycin Trimethoprim Trimethoprim/sul Vancomycin IV PO Other (specify):	stin) famethoxazole	_
	•	□ Penicillin □ Piperacillin/t	tazahaata	m			Other (specify): _		_
REMINDER: Any prior antimicrobial use	that is not noted above should be docur	mented in the	other (spe	ecify) field.					

Version Date: 01/2019



## 26. SUSCEPTIBILITY RESULTS:

Please complete the table below based on the information found in the indicated data source. Shaded antibiotics are required to have the MIC entered into the MuGSI-CM system, if available.

Antibiotic  Amikacin  Amoxicillin/Clavulanate  Ampicillin  Ampicillin/Sulbactam	MIC	Interp	MIC	Interp	MIC	Interp	MIC	Interp	Zone	Interp	MIC	Interp
Amoxicillin/Clavulanate Ampicillin Ampicillin/Sulbactam						ļ		<u> </u>	Diam			
Ampicillin Ampicillin/Sulbactam												
Ampicillin/Sulbactam												
Aztreonam												
Cefazolin												
CEFEPIME												
CEFOTAXIME												
CEFTAZIDIME												
Ceftazidime/Avibactam												
Ceftolozane/Tazobactam												
CEFTRIAXONE												
Cephalothin												
Ciprofloxacin												
COLISTIN												
DORIPENEM												
Doxycycline												
ERTAPENEM												
Fosfomycin												
Gentamicin												
IMIPENEM												
Imipenem-relebactam												
Levofloxacin												
MEROPENEM												
Meropenem-vaborbactam												
Minocycline												
Moxifloxacin												
Nitrofurantoin												
Piperacillin/Tazobactam												
Plazomicin												
POLYMYXIN B												
Rifampin												
Tetracycline												
TIGECYCLINE												
Tobramycin												
Trimethoprim-sulfamethoxazole												

27a. WAS CASE FIRST IDENTIFIED THROUGH AUDIT?	27b. CRF STATUS:	27c. SO INITIALS:	27d. DATE OF ABSTRACTION:
□Yes □No	☐ Complete ☐ Pending ☐ Chart unavailable after 3 requests		
27 <mark>e</mark> , COMMENTS:			

CS295460-B PAGE 4 OF 4